Tirzepatide + Tirzepatide Placebo
ApprovedRecruiting 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Idiopathic Intracranial Hypertension (IIH)
Conditions
Idiopathic Intracranial Hypertension (IIH)
Trial Timeline
Feb 1, 2026 โ Feb 1, 2028
NCT ID
NCT07191873About Tirzepatide + Tirzepatide Placebo
Tirzepatide + Tirzepatide Placebo is a approved stage product being developed by Eli Lilly for Idiopathic Intracranial Hypertension (IIH). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07191873. Target conditions include Idiopathic Intracranial Hypertension (IIH).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07191873 | Approved | Recruiting |
Competing Products
20 competing products in Idiopathic Intracranial Hypertension (IIH)